Ignite Creation Date:
2025-12-24 @ 9:55 PM
Ignite Modification Date:
2026-03-28 @ 8:46 AM
Study NCT ID:
NCT00216632
Status:
COMPLETED
Last Update Posted:
2012-12-07
First Post:
2005-09-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
Sponsor:
Janssen Pharmaceutica N.V., Belgium
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CR003211
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None